PriceTargets.com logo

Kiniksa Pharmaceuticals International - KNSA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $87.38
  • Forecasted Upside: 14.11%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$76.57 As of 09/16/2026 12:53 PM ET
▲ +1.422 (1.89%)

This chart shows the closing price for KNSA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kiniksa Pharmaceuticals International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KNSA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KNSA

Analyst Price Target is $87.38
▲ +14.11% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Kiniksa Pharmaceuticals International in the last 3 months. The average price target is $87.38, with a high forecast of $107.00 and a low forecast of $60.00. The average price target represents a 14.11% upside from the last price of $76.57.

This chart shows the closing price for KNSA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 investment analysts is to moderate buy stock in Kiniksa Pharmaceuticals International. This rating has held steady since July 2026, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/19/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2026
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/17/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/15/2026

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/13/2026Weiss RatingsDowngradeBuy (B-) ➝ Hold (C+)
7/30/2026Zacks ResearchDowngradeStrong-Buy ➝ Hold
7/30/2026The Goldman Sachs GroupBoost TargetBuy ➝ Buy$75.00 ➝ $90.00
7/29/2026Weiss RatingsUpgradeHold (C+) ➝ Buy (B-)
7/29/2026JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$72.00 ➝ $107.00
7/29/2026Canaccord Genuity GroupBoost TargetBuy ➝ Buy$64.00 ➝ $98.00
7/29/2026WedbushBoost TargetOutperform ➝ Outperform$72.00 ➝ $99.00
7/29/2026CitigroupBoost TargetBuy ➝ Buy$60.00 ➝ $100.00
7/23/2026The Goldman Sachs GroupBoost TargetBuy ➝ Buy$60.00 ➝ $75.00
7/13/2026Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$57.00 ➝ $74.00
6/29/2026WedbushBoost TargetOutperform ➝ Outperform$59.00 ➝ $72.00
6/23/2026Weiss RatingsDowngradeBuy (B-) ➝ Hold (C+)
6/17/2026Zacks ResearchUpgradeHold ➝ Strong-Buy
6/8/2026Weiss RatingsUpgradeHold (C+) ➝ Buy (B-)
5/18/2026Zacks ResearchUpgradeStrong Sell ➝ Hold
5/6/2026Weiss RatingsUpgradeHold (C) ➝ Hold (C+)
4/29/2026Canaccord Genuity GroupBoost TargetBuy ➝ Buy$62.00 ➝ $64.00
4/29/2026CitigroupBoost TargetBuy ➝ Buy$50.00 ➝ $60.00
4/29/2026WedbushBoost TargetOutperform ➝ Outperform$58.00 ➝ $59.00
4/29/2026Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$53.00 ➝ $57.00
4/28/2026Jefferies Financial GroupBoost TargetBuy ➝ Buy$58.00 ➝ $71.00
4/21/2026Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
4/17/2026Zacks ResearchDowngradeHold ➝ Strong Sell
4/16/2026WedbushBoost TargetOutperform ➝ Outperform$53.00 ➝ $58.00
2/25/2026Zacks ResearchUpgradeStrong Sell ➝ Hold
2/25/2026Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$50.00 ➝ $53.00
2/25/2026WedbushBoost TargetOutperform ➝ Outperform$50.00 ➝ $53.00
2/19/2026Canaccord Genuity GroupInitiated CoverageBuy$62.00
1/22/2026Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
1/13/2026Zacks ResearchDowngradeHold ➝ Strong Sell
1/13/2026WedbushBoost TargetOutperform ➝ Outperform$48.00 ➝ $50.00
12/2/2025WedbushReiterated RatingOutperform$48.00
10/29/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$45.00 ➝ $55.00
10/28/2025WedbushReiterated RatingOutperform$44.00 ➝ $48.00
10/17/2025CitigroupBoost TargetBuy ➝ Buy$45.00 ➝ $50.00
10/13/2025WedbushBoost TargetOutperform ➝ Outperform$38.00 ➝ $44.00
10/8/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
10/6/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
9/29/2025TD CowenInitiated CoverageBuy$60.00
9/27/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
9/25/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$42.00 ➝ $45.00
7/29/2025Jefferies Financial GroupBoost TargetBuy ➝ Buy$45.00 ➝ $54.00
7/21/2025WedbushReiterated RatingOutperform$36.00
7/9/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$30.00 ➝ $42.00
4/29/2025Jefferies Financial GroupBoost TargetBuy ➝ Buy$40.00 ➝ $45.00
4/16/2025WedbushReiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.00
3/13/2025CitigroupInitiated CoverageBuy$40.00
2/25/2025WedbushReiterated RatingOutperform$34.00
1/13/2025WedbushReiterated RatingOutperform$34.00
11/5/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$39.00 ➝ $40.00
10/30/2024EvercoreBoost TargetOutperform ➝ Outperform$30.00 ➝ $35.00
9/13/2024Jefferies Financial GroupInitiated CoverageBuy$40.00
7/23/2024WedbushBoost TargetOutperform ➝ Outperform$30.00 ➝ $34.00
5/3/2024Wells Fargo & CompanyInitiated CoverageOverweight$34.00
5/1/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$26.00 ➝ $30.00
4/24/2024EvercoreBoost TargetOutperform ➝ Outperform$25.00 ➝ $30.00
4/23/2024WedbushReiterated RatingOutperform$30.00
4/2/2024WedbushReiterated RatingOutperform$28.00 ➝ $30.00
2/28/2024WedbushReiterated RatingOutperform$28.00
1/2/2024WedbushBoost TargetOutperform ➝ Outperform$23.00 ➝ $25.00
10/31/2023WedbushReiterated RatingOutperform$23.00
3/9/2023JPMorgan Chase & Co.Boost TargetOverweight$19.00 ➝ $20.00
3/1/2023WedbushLower Target$26.00 ➝ $20.00
12/29/2021Bank of AmericaLower TargetBuy$37.00 ➝ $34.00
11/2/2021The Goldman Sachs GroupReiterated RatingBuy$34.00
(Data available from 9/16/2021 forward)

News Sentiment Rating

1.30 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2026
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2026
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2026
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2026
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2026
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2026
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/16/2026

Current Sentiment

  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Kiniksa Pharmaceuticals International logo
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Read More

Today's Range

Now: $76.57
Low: $74.91
High: $76.87

50 Day Range

MA: $73.77
Low: $60.94
High: $81.03

52 Week Range

Now: $76.57
Low: $35.20
High: $82.94

Volume

96,678 shs

Average Volume

688,431 shs

Market Capitalization

$5.97 billion

P/E Ratio

79.04

Dividend Yield

N/A

Beta

0.09

Frequently Asked Questions

What sell-side analysts currently cover shares of Kiniksa Pharmaceuticals International?

The following equities research analysts have issued stock ratings on Kiniksa Pharmaceuticals International in the last twelve months: Canaccord Genuity Group Inc., Citigroup Inc., Jefferies Financial Group Inc., JPMorgan Chase & Co., TD Cowen, The Goldman Sachs Group, Inc., Wall Street Zen, Wedbush, Weiss Ratings, Wells Fargo & Company, and Zacks Research.
View the latest analyst ratings for KNSA.

What is the current price target for Kiniksa Pharmaceuticals International?

0 Wall Street analysts have set twelve-month price targets for Kiniksa Pharmaceuticals International in the last year. Their average twelve-month price target is $87.38, suggesting a possible upside of 14.1%. JPMorgan Chase & Co. has the highest price target set, predicting KNSA will reach $107.00 in the next twelve months. TD Cowen has the lowest price target set, forecasting a price of $60.00 for Kiniksa Pharmaceuticals International in the next year.
View the latest price targets for KNSA.

What is the current consensus analyst rating for Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International currently has 2 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for KNSA.

What other companies compete with Kiniksa Pharmaceuticals International?

Other companies that are similar to Kiniksa Pharmaceuticals International include United Therapeutics, Genmab A/S, Ascendis Pharma A/S, Exelixis and BridgeBio Pharma. Learn More about companies similar to Kiniksa Pharmaceuticals International.

How do I contact Kiniksa Pharmaceuticals International's investor relations team?

Kiniksa Pharmaceuticals International's physical mailing address is 105 Piccadilly, Second Floor, London, W1j 7nj. The company's listed phone number is (781) 431-9100 and its investor relations email address is [email protected]. The official website for Kiniksa Pharmaceuticals International is www.kiniksa.com. Learn More about contacing Kiniksa Pharmaceuticals International investor relations.